Rational, Computer-Enabled Peptide Drug Design: Principles, Methods, Applications and Future Directions

References

• Fosgerau K , HoffmannT. Peptide therapeutics: current status and future directions. Drug Discov. Today20 (1), 122–128 (2015).
   PubMed Web of Science ®Google Scholar
• Kaspar AA , ReichertJM. Future directions for peptide therapeutics development. Drug Discov. Today18 (17–18), 807–817 (2013).
   PubMed Web of Science ®Google Scholar
• Bashiruddin NK , SugaH. Construction and screening of vast libraries of natural product-like macrocyclic peptides using in vitro display technologies. Curr. Opin. Chem. Biol.24, 131–138 (2015).
   PubMed Web of Science ®Google Scholar
• Lian W , UpadhyayaP, RhodesCA, LiuY, PeiD. Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-alpha antagonist. J. Am. Chem. Soc.135 (32), 11990–11995 (2013).
   PubMed Web of Science ®Google Scholar
• Hu Y , BajorathJ. High-resolution view of compound promiscuity. F1000 Research2, 144 (2013).
   PubMedGoogle Scholar
• Nicolaou CA , BrownN. Multi-objective optimization methods in drug design. Drug Discov. Today Technol.10 (3), e427–e435 (2013).
   PubMedGoogle Scholar
• Frank AO , VangamudiB, FeldkampMDet al. Discovery of a potent stapled helix peptide that binds to the 70N domain of replication protein A. J. Med. Chem.57 (6), 2455–2461 (2014).
   PubMed Web of Science ®Google Scholar
• Koolpe M , BurgessR, DailM, PasqualeEB. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J. Biol. Chem.280 (17), 17301–17311 (2005).
   PubMed Web of Science ®Google Scholar
• Hosseini M , JiangL, SorensenHPet al. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs. Mol. Pharmacol.80 (4), 585–597 (2011).
   PubMed Web of Science ®Google Scholar
• Kim D , LeeIH, KimSet al. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res.74 (8), 2144–2151 (2014).
   PubMed Web of Science ®Google Scholar
• London N , GullaS, KeatingAE, Schueler-FurmanO. In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2. Biochemistry51 (29), 5841–5850 (2012).
   PubMed Web of Science ®Google Scholar
• Chen Z , HuY, HongJet al. Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel. Sci. Rep.5, 9881 (2015).
   PubMed Web of Science ®Google Scholar
• Quartararo JS , WuP, KritzerJA. Peptide bicycles that inhibit the Grb2 SH2 domain. ChemBioChem13 (10), 1490–1496 (2012).
   PubMed Web of Science ®Google Scholar
• Williams BA , DiehneltCW, BelcherPet al. Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds. J. Am. Chem. Soc.131 (47), 17233–17241 (2009).
   PubMed Web of Science ®Google Scholar
• Diehnelt CW , ShahM, GuptaNet al. Discovery of high-affinity protein binding ligands--backwards. PLoS ONE5 (5), e10728 (2010).
   PubMed Web of Science ®Google Scholar
• Brauer F , SchmidtK, ZahnRCet al. A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. Antimicrob. Agents Chemother.57 (2), 679–688 (2013).
   PubMed Web of Science ®Google Scholar
• Bennett CL , JacobS, HymesJ, UsvyatLA, MadduxFW. Anaphylaxis and hypotension after administration of peginesatide. N. Engl. J. Med.370 (21), 2055–2056 (2014).
   PubMed Web of Science ®Google Scholar
• Weinstock MT , FrancisJN, RedmanJS, KayMS. Protease-resistant peptide design-empowering nature's fragile warriors against HIV. Biopolymers98 (5), 431–442 (2012).
   PubMed Web of Science ®Google Scholar
• Baeriswyl V , HeinisC. Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases. Protein Eng. Des. Sel.26 (1), 81–89 (2013).
   PubMed Web of Science ®Google Scholar
• Galati R , VerdinaA, FalascaG, ChersiA. Increased resistance of peptides to serum proteases by modification of their amino groups. Z. Naturforsch.58 (7–8), 558–561 (2003).
   Google Scholar
• Nguyen LT , ChauJK, PerryNA, De BoerL, ZaatSA, VogelHJ. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS ONE5 (9), (2010).
   Web of Science ®Google Scholar
• Heard KR , WuW, LiYet al. A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates. J. Med. Chem.56 (21), 8339–8351 (2013).
   PubMed Web of Science ®Google Scholar
• Walensky LD , BirdGH. Hydrocarbon-stapled peptides: principles, practice, and progress. J. Med. Chem.57 (15), 6275–6288 (2014).
   PubMed Web of Science ®Google Scholar
• Howell SM , FiaccoSV, TakahashiTTet al. Serum stable natural peptides designed by mRNA display. Sci. Rep.4, 6008 (2014).
   PubMed Web of Science ®Google Scholar
• Sharma S , SinghR, RanaS. Bioactive peptides: a review. Int. J. Bioautomation15 (4), 223–250 (2011).
   Google Scholar
• Tsomaia N . Peptide therapeutics: targeting the undruggable space. Eur. J. Med. Chem.94, 459–470 (2015).
   PubMed Web of Science ®Google Scholar
• Ano R , KimuraY, ShimaM, MatsunoR, UenoT, AkamatsuM. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem.12 (1), 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Rezai T , BockJE, ZhouMV, KalyanaramanC, LokeyRS, JacobsonMP. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc.128 (43), 14073–14080 (2006).
   PubMed Web of Science ®Google Scholar
• Rezai T , YuB, MillhauserGL, JacobsonMP, LokeyRS. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc.128 (8), 2510–2511 (2006).
   PubMed Web of Science ®Google Scholar
• White TR , RenzelmanCM, RandACet al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat. Chem. Biol.7 (11), 810–817 (2011).
   PubMed Web of Science ®Google Scholar
• Rafi SB , HearnBR, VedanthamP, JacobsonMP, RensloAR. Predicting and improving the membrane permeability of peptidic small molecules. J. Med. Chem.55 (7), 3163–3169 (2012).
   PubMed Web of Science ®Google Scholar
• Rand AC , LeungSS, EngHet al. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance. MedChemComm3 (10), 1282–1289 (2012).
   PubMed Web of Science ®Google Scholar
• Bockus AT , LexaKW, PyeCRet al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem.58 (11), 4581–4589 (2015).
   PubMed Web of Science ®Google Scholar
• Hewitt WM , LeungSS, PyeCRet al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc.137 (2), 715–721 (2015).
   PubMed Web of Science ®Google Scholar
• Wang CK , NorthfieldSE, SwedbergJEet al. Exploring experimental and computational markers of cyclic peptides: charting islands of permeability. Eur. J. Med. Chem.97, 202–213 (2015).
   PubMed Web of Science ®Google Scholar
• Kwon YU , KodadekT. Quantitative comparison of the relative cell permeability of cyclic and linear peptides. Chem. Biol.14 (6), 671–677 (2007).
   PubMedGoogle Scholar
• Mikol V , KallenJ, PfluglG, WalkinshawMD. X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J. Mol. Biol.234 (4), 1119–1130 (1993).
   PubMed Web of Science ®Google Scholar
• Hughes JD , BlaggJ, PriceDAet al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett.18 (17), 4872–4875 (2008).
   PubMed Web of Science ®Google Scholar
• Altschuh D , VixO, ReesB, ThierryJC. A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. Science256 (5053), 92–94 (1992).
   PubMed Web of Science ®Google Scholar
• Sugahara KN , TeesaluT, KarmaliPPet al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science328 (5981), 1031–1035 (2010).
   PubMed Web of Science ®Google Scholar
• Roth L , AgemyL, KotamrajuVRet al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene31 (33), 3754–3763 (2012).
   PubMed Web of Science ®Google Scholar
• Alberici L , RothL, SugaharaKNet al. De novo design of a tumor-penetrating peptide. Cancer Res.73 (2), 804–812 (2013).
   PubMed Web of Science ®Google Scholar
• Teesalu T , SugaharaKN, RuoslahtiE. Tumor-penetrating peptides. Front. Oncol.3, 216 (2013).
   PubMedGoogle Scholar
• Pang HB , BraunGB, FrimanTet al. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat. Commun.5, 4904 (2014).
   PubMed Web of Science ®Google Scholar
• Sugahara KN , BraunGB, De MendozaTHet al. Tumor-penetrating iRGD peptide inhibits metastasis. Mol. Cancer Ther.14 (1), 120–128 (2015).
   PubMed Web of Science ®Google Scholar
• Lu J , ChengY, ZhangGet al. Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma. Mol. Med. Rep.12 (2), 2668–2676 (2015).
   PubMed Web of Science ®Google Scholar
• Barr MP , GraySG, GatelyKet al. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. Mol. Cancer14 (1), 45 (2015).
   PubMedGoogle Scholar
• Jiang H , XiQ, WangF, SunZ, HuangZ, QiL. Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma. Mol. Med. Rep.12 (2), 2114–2120 (2015).
   PubMed Web of Science ®Google Scholar
• Chaudhary B , ElkordE. Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. Expert Opin. Ther. Targets19 (2), 147–161 (2015).
   PubMed Web of Science ®Google Scholar
• Tortorella S , KaragiannisTC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J. Membrane Biol.247 (4), 291–307 (2014).
   PubMed Web of Science ®Google Scholar
• Fang L , WangM, GouS, LiuX, ZhangH, CaoF. Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs. J. Med. Chem.57 (3), 1116–1120 (2014).
   PubMed Web of Science ®Google Scholar
• Han X , SunJ, WangY, HeZ. PepT1, ASBT-linked prodrug strategy to improve oral bioavailability and tissue targeting distribution. Curr. Drug Metabol.16 (1), 71–83 (2015).
   PubMed Web of Science ®Google Scholar
• Jin SE , JinHE, HongSS. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics. Expert Opin. Ther. Targets doi:10.1517/14728222.2015.1044975 (2015) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Kapoor P , SinghH, GautamA, ChaudharyK, KumarR, RaghavaGP. TumorHoPe: a database of tumor homing peptides. PLoS ONE7 (4), e35187 (2012).
   PubMed Web of Science ®Google Scholar
• Fazen CH , ValentinD, FairchildTJ, DoyleRP. Oral delivery of the appetite suppressing peptide hPYY(3–36) through the vitamin B12 uptake pathway. J. Med. Chem.54 (24), 8707–8711 (2011).
   PubMed Web of Science ®Google Scholar
• Clardy-James S , ChepurnyOG, LeechCA, HolzGG, DoyleRP. Synthesis, characterization and pharmacodynamics of vitamin-B12-conjugated glucagon-like peptide-1. ChemMedChem8 (4), 582–586 (2013).
   PubMed Web of Science ®Google Scholar
• Moos T , MorganEH. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol.20 (1), 77–95 (2000).
   PubMed Web of Science ®Google Scholar
• Staquicini FI , OzawaMG, MoyaCAet al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest.121 (1), 161 (2011).
   PubMed Web of Science ®Google Scholar
• Demeule M , ReginaA, CheCet al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther.324 (3), 1064–1072 (2008).
   PubMed Web of Science ®Google Scholar
• Demeule M , BeaudetN, RéginaAet al. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J. Clin. Invest.124 (3), 1199 (2014).
   PubMed Web of Science ®Google Scholar
• Regina A , DemeuleM, CheCet al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol.155 (2), 185–197 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar P , WuH, McBrideJLet al. Transvascular delivery of small interfering RNA to the central nervous system. Nature448 (7149), 39–43 (2007).
   PubMed Web of Science ®Google Scholar
• Liu Y , GuoY, AnSet al. Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease. PLoS ONE8 (5), e62905 (2013).
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti L , SeowY, YinH, BettsC, LakhalS, WoodMJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol.29 (4), 341–345 (2011).
   PubMed Web of Science ®Google Scholar
• Chen W , ZhanC, GuBet al. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J. Drug Target.19 (3), 228–234 (2011).
   PubMed Web of Science ®Google Scholar
• Van Dorpe S , BronselaerA, NielandtJet al. Brainpeps: the blood-brain barrier peptide database. Brain Struct. Funct.217 (3), 687–718 (2012).
   PubMed Web of Science ®Google Scholar
• Hughes FM Jr , ShanerBE, BrowerJO, WoodsRJ, DixTA. Development of a Peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain. Open Med. Chem. J.7, 16–22 (2013).
   PubMedGoogle Scholar
• Bockus AT , LexaKW, PyeCRet al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem.58 (11), 4581–4589 (2015).
   PubMed Web of Science ®Google Scholar
• Nielsen DS , HoangHN, LohmanRJet al. Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew. Chem. Int. Ed. Engl.53 (45), 12059–12063 (2014).
   PubMed Web of Science ®Google Scholar
• Ogawa T , MiyamaeT, MurayamaKet al. Synthesis and structure-activity relationships of an orally available and long-acting analgesic peptide, N(alpha)-amidino-Tyr-D-Arg-Phe-MebetaAla-OH (ADAMB). J. Med. Chem.45 (23), 5081–5089 (2002).
   PubMed Web of Science ®Google Scholar
• Hess S , LindeY, OvadiaOet al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J. Med. Chem.51 (4), 1026–1034 (2008).
   PubMed Web of Science ®Google Scholar
• Campana C , RegazziMB, BuggiaI, MolinaroM. Clinically significant drug interactions with cyclosporin. An update. Clin. Pharmacokinet.30 (2), 141–179 (1996).
   PubMed Web of Science ®Google Scholar
• Kuroda D , ShiraiH, JacobsonMP, NakamuraH. Computer-aided antibody design. Protein Eng. Des. Sel.25 (10), 507–521 (2012).
   PubMed Web of Science ®Google Scholar
• Rentzsch R , RenardBY. Docking small peptides remains a great challenge: an assessment using AutoDock Vina. Brief Bioinform. doi:10.1093/bib/bbv008 (2015) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Pike DH , NandaV. Empirical estimation of local dielectric constants: toward atomistic design of collagen mimetic peptides. Biopolymers104 (4), 360–370 (2015).
   PubMed Web of Science ®Google Scholar
• Audie J , SwansonJ. Recent work in the development and application of protein-peptide docking. Future Med. Chem.4 (12), 1619–1644 (2012).
   PubMed Web of Science ®Google Scholar
• Das R . Four small puzzles that Rosetta doesn't solve. PLoS ONE6 (5), e20044 (2011).
   PubMed Web of Science ®Google Scholar
• TumorHoPe – Tumor Homing Peptide Database . http://crdd.osdd.net/raghava/tumorhope.
   Google Scholar
• Volpe DA . Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med. Chem.3 (16), 2063–2077 (2011).
   PubMed Web of Science ®Google Scholar
• Brainpeps . http://brainpeps.ugent.be.
   Google Scholar
• Hansen MR , VillarHO, FeyfantE. Development of an informatics platform for therapeutic protein and peptide analytics. J. Chem. Inform. Model.53 (10), 2774–2779 (2013).
   PubMed Web of Science ®Google Scholar
• Altoris - SARvision . www.chemapps.com/sarvision-biologics.
   Google Scholar
• Thevenet P , ShenY, MaupetitJ, GuyonF, DerreumauxP, TufferyP. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res.40, W288–W293 (2012).
   PubMed Web of Science ®Google Scholar
• PEP-FOLD Server . http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD.
   Google Scholar
• Vanhee P , ReumersJ, StricherFet al. PepX: a structural database of non-redundant protein-peptide complexes. Nucleic Acids Res.38, D545–D551 (2010).
   PubMed Web of Science ®Google Scholar
• PepX . www.switchlab.org/bioinformatics/pepx.
   Google Scholar
• Das AA , SharmaOP, KumarMS, KrishnaR, MathurPP. PepBind: a comprehensive database and computational tool for analysis of protein-peptide interactions. Genomics Proteomics Bioinform.11 (4), 241–246 (2013).
   PubMedGoogle Scholar
• PepBind . http://pepbind.bicpu.edu.in.
   Google Scholar
• London N , Movshovitz-AttiasD, Schueler-FurmanO. The structural basis of peptide-protein binding strategies. Structure18 (2), 188–199 (2010).
   PubMed Web of Science ®Google Scholar
• London N , RavehB, CohenE, FathiG, Schueler-FurmanO. Rosetta FlexPepDock web server--high resolution modeling of peptide-protein interactions. Nucleic Acids Res.39, W249–W253 (2011).
   PubMed Web of Science ®Google Scholar
• FlexPepDock . http://flexpepdock.furmanlab.cs.huji.ac.il.
   Google Scholar
• Raveh B , LondonN, ZimmermanL, Schueler-FurmanO. Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors. PLoS ONE6 (4), e18934 (2011).
   PubMed Web of Science ®Google Scholar
• Li H , LuL, ChenR, QuanL, XiaX, LuQ. PaFlexPepDock: parallel ab-initio docking of peptides onto their receptors with full flexibility based on Rosetta. PLoS ONE9 (5), e94769 (2014).
   PubMed Web of Science ®Google Scholar
• Ben-Shimon A , NivMY. AnchorDock: blind and flexible anchor-driven peptide docking. Structure23 (5), 929–940 (2015).
   PubMed Web of Science ®Google Scholar
• Trellet M , MelquiondAS, BonvinAM. A unified conformational selection and induced fit approach to protein-peptide docking. PLoS ONE8 (3), e58769 (2013).
   PubMed Web of Science ®Google Scholar
• HADDOCK . http://haddocking.org.
   Google Scholar
• Kurcinski M , JamrozM, BlaszczykM, KolinskiA, KmiecikS. CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site. Nucleic Acids Res.43 (W1), W419–W424 (2015).
   PubMed Web of Science ®Google Scholar
• CABS-Dock . http://biocomp.chem.uw.edu.pl/CABSdock.
   Google Scholar
• Lee H , HeoL, LeeMS, SeokC. GalaxyPepDock: a protein-peptide docking tool based on interaction similarity and energy optimization. Nucleic Acids Res.43 (W1), W431–W435 (2015).
   PubMed Web of Science ®Google Scholar
• GalaxyPepDock . http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=PEPDOCK.
   Google Scholar
• Yan C , ZouX. Predicting peptide binding sites on protein surfaces by clustering chemical interactions. J. Comput. Chem.36 (1), 49–61 (2015).
   PubMed Web of Science ®Google Scholar
• Verschueren E , VanheeP, RousseauF, SchymkowitzJ, SerranoL. Protein-peptide complex prediction through fragment interaction patterns. Structure21 (5), 789–797 (2013).
   PubMed Web of Science ®Google Scholar
• Saladin A , ReyJ, ThevenetP, ZachariasM, MoroyG, TufferyP. PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces. Nucleic Acids Res.42, W221–W226 (2014).
   PubMed Web of Science ®Google Scholar
• PEP-Site Finder . http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-SiteFinder.
   Google Scholar
• Unal EB , GursoyA, ErmanB. VitAL: Viterbi algorithm for de novo peptide design. PLoS ONE5 (6), e10926 (2010).
   PubMed Web of Science ®Google Scholar
• Bhattacherjee A , WallinS. Exploring protein-peptide binding specificity through computational peptide screening. PLoS Comput. Biol.9 (10), e1003277 (2013).
   PubMed Web of Science ®Google Scholar
• Rivera CG , RoscaEV, PandeyNB, KoskimakiJE, BaderJS, PopelAS. Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J. Med. Chem.54 (19), 6492–6500 (2011).
   PubMed Web of Science ®Google Scholar
• Du QS , HuangRB, ChouKC. Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Peptide Sci.9 (3), 248–260 (2008).
   PubMed Web of Science ®Google Scholar
• Du QS , MaY, XieNZ, HuangRB. Two-level QSAR network (2L-QSAR) for peptide inhibitor design based on amino acid properties and sequence positions. SAR QSAR Environ. Res.25 (10), 837–851 (2014).
   PubMed Web of Science ®Google Scholar
• Du QS , WeiYT, PangZW, ChouKC, HuangRB. Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction. Protein Eng. Des. Sel.20 (9), 417–423 (2007).
   PubMed Web of Science ®Google Scholar
• Du QS , XieNZ, HuangRB. Recent development of Peptide drugs and advance on theory and methodology of Peptide inhibitor design. Med. Chem.11 (3), 235–247 (2015).
   PubMed Web of Science ®Google Scholar
• Bhonsle JB , ClarkT, BartolottiL, HicksRP. A brief overview of antimicrobial peptides containing unnatural amino acids and ligand-based approaches for peptide ligands. Curr. Top. Med. Chem.13 (24), 3205–3224 (2013).
   PubMed Web of Science ®Google Scholar
• Giguere S , LavioletteF, MarchandMet al. Machine learning assisted design of highly active peptides for drug discovery. PLoS Comput. Biol.11 (4), e1004074 (2015).
   PubMed Web of Science ®Google Scholar
• Beaufays J , LinsL, ThomasA, BrasseurR. In silico predictions of 3D structures of linear and cyclic peptides with natural and non-proteinogenic residues. J. Peptide Sci.18 (1), 17–24 (2012).
   PubMed Web of Science ®Google Scholar
• Klepeis JL , Lindorff-LarsenK, DrorRO, ShawDE. Long-timescale molecular dynamics simulations of protein structure and function. Curr. Opin. Struct. Biol.19 (2), 120–127 (2009).
   PubMed Web of Science ®Google Scholar
• Lindorff-Larsen K , PianaS, DrorRO, ShawDE. How fast-folding proteins fold. Science334 (6055), 517–520 (2011).
   PubMed Web of Science ®Google Scholar
• Denisiuk A , SchubertV, WolterFE, IrranE, TrouillasP, SussmuthRD. Conformational investigation of antibiotic proximicin by X-ray structure analysis and quantum studies suggest a stretched conformation of this type of gamma-peptide. Bioorg. Med. Chem.21 (12), 3582–3589 (2013).
   PubMed Web of Science ®Google Scholar
• Han C , WangJ. Influence of an unnatural amino acid side chain on the conformational dynamics of peptides. ChemPhysChem13 (6), 1522–1534 (2012).
   PubMed Web of Science ®Google Scholar
• Improta R , VitaglianoL, EspositoL. Bond distances in polypeptide backbones depend on the local conformation. Acta Crystallogr. D Biol. Crystallogr.71 (Pt 6), 1272–1283 (2015).
   PubMedGoogle Scholar
• Haslach EM , HuangH, DirainMet al. Identification of tetrapeptides from a mixture based positional scanning library that can restore nM full agonist function of the L106P, I69T, I102S, A219V, C271Y, and C271R human melanocortin-4 polymorphic receptors (hMC4Rs). J. Med. Chem.57 (11), 4615–4628 (2014).
   PubMed Web of Science ®Google Scholar
• Walshe VA , HattotuwagamaCK, DoytchinovaIA, FlowerDR. A dataset of experimental HLA-B*2705 peptide binding affinities. Dataset Papers in Science2014, 4 (2014).
   Google Scholar
• Fransson R , SkoldC, KratzJMet al. Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1–7 binding site and with improved metabolic stability and cell permeability. J. Med. Chem.56 (12), 4953–4965 (2013).
   PubMed Web of Science ®Google Scholar
• Tal-Gan Y , HurevichM, KleinSet al. Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J. Med. Chem.54 (14), 5154–5164 (2011).
   PubMed Web of Science ®Google Scholar
• Phan J , LiZ, KasprzakAet al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J. Biol. Chem.285 (3), 2174–2183 (2010).
   PubMed Web of Science ®Google Scholar
• Smadbeck J , PetersonMB, ZeeBMet al. De novo peptide design and experimental validation of histone methyltransferase inhibitors. PLoS ONE9 (4), e95535 (2014).
   PubMed Web of Science ®Google Scholar
• Feng S , ZouL, NiQet al. Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor. Cell Biochem. Biophys.70 (3), 1913–1921 (2014).
   PubMed Web of Science ®Google Scholar
• Roberts KE , CushingPR, BoisguerinP, MaddenDR, DonaldBR. Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity. PLoS Comput. Biol.8 (4), e1002477 (2012).
   PubMed Web of Science ®Google Scholar
• Kilian TM , KlotingN, BergmannRet al. Rational design of dual peptides targeting ghrelin and Y receptors to regulate food intake and body weight. J. Med. Chem.58 (10), 4180–4193 (2015).
   PubMed Web of Science ®Google Scholar
• Wang CK , GruberCW, CemazarMet al. Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis. ACS Chem. Biol.9 (1), 156–163 (2014).
   PubMed Web of Science ®Google Scholar
• Fung HK , FloudasCA, TaylorMS, ZhangL, MorikisD. Toward full-sequence de novo protein design with flexible templates for human beta-defensin-2. Biophys. J.94 (2), 584–599 (2008).
   PubMed Web of Science ®Google Scholar
• Bellows-Peterson ML , FungHK, FloudasCAet al. De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. J. Med. Chem.55 (9), 4159–4168 (2012).
   PubMed Web of Science ®Google Scholar
• Halai R , Bellows-PetersonML, BranchettWet al. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. Eur. J. Pharmacol.745, 176–181 (2014).
   PubMed Web of Science ®Google Scholar
• Gorham RD Jr , ForestDL, KhouryGAet al. New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics. J. Med. Chem.58 (2), 814–826 (2015).
   PubMed Web of Science ®Google Scholar
• Bellows ML , TaylorMS, ColePAet al. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. Biophys. J.99 (10), 3445–3453 (2010).
   PubMed Web of Science ®Google Scholar
• Wang CK , NorthfieldSE, CollessBet al. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc. Natl Acad. Sci. USA111 (49), 17504–17509 (2014).
   PubMed Web of Science ®Google Scholar
• Jagadish K , CamareroJA. Cyclotides, a promising molecular scaffold for peptide-based therapeutics. Biopolymers94 (5), 611–616 (2010).
   PubMed Web of Science ®Google Scholar
• Poth AG , ChanLY, CraikDJ. Cyclotides as grafting frameworks for protein engineering and drug design applications. Biopolymers100 (5), 480–491 (2013).
   PubMed Web of Science ®Google Scholar
• Wong CT , RowlandsDK, WongCHet al. Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew. Chem. Int. Ed. Engl.51 (23), 5620–5624 (2012).
   PubMed Web of Science ®Google Scholar